Гимсилумаб (Gimsilumab)
Международное непатентованное наименование
Гимсилумаб (Gimsilumab)
Торговое наименование
-
Производитель, страна
Roivant Sciences, Switzerland
Механизм действия
Gimsilumab is a clinical-stage, fully human anti-granulocyte-macrophage colony stimulating factor (GM-CSF) monoclonal antibody. GM-CSF is a cytokine implicated in many autoimmune disorders that acts as a pro-inflammatory signal, prompting macrophages to launch an immune cascade that ultimately results in tissue damage.
Публикации COVID-19
Zhou Y, Fu B, Zheng X, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. Pre-Print. 2020.
Siddiqi HK and Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transpl. 2020. https://doi.org/10.1016/j.healun.2020.03.012.
Клинические исследования
1.
Название протокола
An adaptive, randomized, double-blind, placebo-controlled, multi-center pivotal trial evaluating the impact of intravenous treatment with gimsilumab on mortality in COVID-19 patients with lung injury or ARDS.
Дата начала и окончания КИ
April 2020 - July 2020
Название организации, проводящей КИ
Roivant Sciences
Страны
USA
Фаза
IV
Кол-во пациентов
270